IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law TMCnet News [October 11, 2026] | / | IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced on September 23, 2026, that its proof-of-concept study of IMVT-1402 failed to achieve a statisticaly significant result on its primary endpoint. The Company added that it plans to stop developing the drug for treatment of cutaneous lupus erythematosus. Based on this news, shares of Immunovant fell by nearly 7.4% on the same day. If you are a shareholder who suffered a loss, click here to participate. Fog Computing World also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach Fog Computing World through the firm's website at www.schallfirm.com, or by email at [email protected]. WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on businesswire.com: https://www.businesswire.com/news/home/20261011801778/en/ [ Back To TMCnet.com's Homepage] |

Immunovant announces topline results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus. September 23, 2026 07:00 ET | Source: Immunovant Inc. * Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 * Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE * IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies * All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) - Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE. "On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care. Their contributions advance our understanding of FcRn inhibition in autoimmune disease and will inform our work going forward," said Eric Venker, M.D., Pharm.D., Chief Executive Officer of Immunovant. Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402 across multiple autoimmune diseases with significant unmet need, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren's disease. About the Proof-of-Concept Study of IMVT-1402 in CLE The proof-of-concept clinical study (NCT06980805) of IMVT-1402 (imeroprubart) in CLE is a randomized, double-blind, placebo-controlled, global trial that assessed the safety and efficacy of IMVT-1402 in adult patients with CLE. The study enrolled 57 patients. In Period 1, patients were randomized to IMVT-1402 vs. placebo for a 12-week treatment period. The primary endpoint was the percent change from Period 1 baseline in CLASI-A score at Week 12. About Immunovant Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," "may," "might," "will," "would," "should," "expect," "believe," "estimate," "design," "plan," "intend," and other similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding Immunovant's plans and progress towards developing IMVT-1402 across a broad range of indications. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant's product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant's scientific approach, clinical trial design, indication selection, regulatory strategy, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant's business operations and supply chain, including its clinical development plans and timelines; Immunovant's business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402; Immunovant is at various stages of clinical development for IMVT-1402; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled "Risk Factors" in Immunovant's Annual Report on Form 10-K filed with the SEC on May 20, 2026, and Immunovant's subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts: Investors Keyur Parekh [email protected] Media Stephanie Lee [email protected]

FY2031 EPS estimate for Immunovant decreased by analyst. August 17, 2026 Key points. * HC Wainwright lowered Immunovant's FY2031 EPS estimate to $3.80 from $4.13, while maintaining a Buy rating and a $40 price target. * Immunovant reported quarterly EPS of -$0.75, missing the consensus estimate of -$0.63, while revenue of $7.09 million matched expectations. * Analyst sentiment remains broadly positive, with six Buy ratings, three Holds and one Sell; the consensus price target is $44.00. Shares recently traded at $41.82, near their 52-week high. * Five stocks we like better than Immunovant. Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Investment analysts at HC Wainwright decreased their FY2031 earnings per share (EPS) estimates for shares of Immunovant in a report issued on Friday, August 7th. HC Wainwright analyst D. Tsao now expects that the company will earn $3.80 per share for the year, down from their prior forecast of $4.13. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Immunovant's current full-year earnings is ($2.72) per share. Immunovant (NASDAQ:IMVT - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The company had revenue of $7.09 million for the quarter, compared to analyst estimates of $7.09 million. During the same period in the prior year, the company posted ($0.71) EPS. Other equities research analysts have also issued research reports about the stock. Truist Financial lifted their target price on shares of Immunovant from $23.00 to $30.00 and gave the company a "hold" rating in a research note on Friday, May 22nd. Citigroup upped their price target on shares of Immunovant from $57.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. JPMorgan Chase & Co. increased their price objective on Immunovant from $47.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Bank of America lifted their price objective on Immunovant from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein upgraded Immunovant to a "hold" rating in a research note on Wednesday, July 29th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Immunovant has an average rating of "Moderate Buy" and a consensus price target of $44.00. Immunovant stock performance. Immunovant stock opened at $41.82 on Monday. The firm has a market cap of $8.64 billion, a PE ratio of -14.83 and a beta of 0.77. The firm's 50 day moving average price is $38.19 and its two-hundred day moving average price is $31.15. Immunovant has a twelve month low of $14.47 and a twelve month high of $42.92. Insider activity. In other news, CTO Jay S. Stout sold 40,000 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $38.31, for a total transaction of $1,532,400.00. Following the transaction, the chief technology officer owned 211,685 shares in the company, valued at $8,109,652.35. This represents a 15.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tuyl Christopher Van sold 17,824 shares of the firm's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $38.31, for a total transaction of $682,837.44. Following the transaction, the insider owned 180,597 shares in the company, valued at $6,918,671.07. This represents a 8.98% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 324,810 shares of company stock valued at $11,350,166. 1.90% of the stock is currently owned by company insiders. Institutional investors weigh in on Immunovant. Several institutional investors and hedge funds have recently modified their holdings of IMVT. Geneos Wealth Management Inc. acquired a new position in Immunovant during the fourth quarter worth $25,000. Strs Ohio bought a new position in Immunovant during the first quarter valued at about $27,000. PNC Financial Services Group Inc. lifted its position in shares of Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company's stock worth $46,000 after buying an additional 1,646 shares during the last quarter. Quarry LP lifted its position in shares of Immunovant by 94.9% in the fourth quarter. Quarry LP now owns 3,000 shares of the company's stock worth $76,000 after buying an additional 1,461 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Immunovant during the 2nd quarter worth about $87,000. Institutional investors and hedge funds own 47.08% of the company's stock. About Immunovant. Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia. The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Immunovant, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list. While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.